EIF2S1

Across TCGA pan-cancer cohorts, EIF2S1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EIF2S1 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EIF2S1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated EIF2S1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, GBM, and LUAD are the cancer types where EIF2S1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	1.000	0.537	.008	29	view →
GBM	DFS	Tertile	All	0.670	0.853	.015	8	view →
LUAD	DFS	Quartile	All	0.994	0.834	.037	6	view →
HNSC	OS	Median	III,IV	1.000	0.449	.023	5	view →
OV	DFS	Median	All	0.874	1.000	.047	4	view →
CCRCC	DFS	Quartile	All	0.586	0.899	.010	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EIF2S1–PDAC (OS)

Open the PDAC breakdown →